Headway vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 74)
Headway logo

Headway

LeaderHealthcare

Mental Health Provider Network & Insurance Matching

Headway is the largest mental health platform connecting patients to in-network therapists and psychiatrists; $2.3B valuation after $100M Series D in July 2024; $321M raised; 34,000+ providers across all 50 US states.

AI VisibilityBeta
Overall Score
B74
Category Rank
#83 of 596
AI Consensus
81%
Trend
stable
Per Platform
ChatGPT
75
Perplexity
78
Gemini
72

About

Headway is the United States' largest mental health platform by provider network, connecting individuals seeking therapy and psychiatric care with in-network mental health professionals covered by their insurance. Founded in 2019 and headquartered in New York, Headway builds the infrastructure layer that allows mental health providers — therapists and psychiatrists — to easily accept insurance, handle billing and credentialing automatically, and manage their patient panels through a streamlined practice management platform. This eliminates the administrative burden that has historically caused the majority of mental health providers to operate as cash-pay only, significantly reducing access barriers for patients.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

74
Overall Score
93
#83
Category Rank
#1
81
AI Consensus
80
stable
Trend
stable
75
ChatGPT
94
78
Perplexity
89
72
Gemini
94
74
Claude
92
70
Grok
98

Key Details

Category
Mental Health Provider Network & Insurance Matching
Enterprise
Tier
Leader
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.